摘要
目的探讨不同药物经阴道上药治疗宫颈高危型人乳头瘤病毒(HR-HPV)感染的临床疗效。方法将符合纳入标准的240例患者分为4组,治疗组1采用锡类散;治疗组2采用重组人干扰素α-2b栓;治疗组3采用瑞贝生女性抗毒洁阴复合剂;对照组采用生理盐水涂擦宫颈。4组均采用阴道宫颈上药,于月经干净后第3天开始上药,隔日1次,共6周,经期停药。观察治疗效果,并进行对比分析。结果(1)HR-HPV转阴率:治疗组均有明显升高,且治疗组1优于其他组(P<0.05);(2)HR-HPVDNA定量:治疗组均有明显下降,治疗组1优于其他组(P<0.05);(3)宫颈细胞学转阴率:治疗组组间比较差异无统计学意义(P>0.05),治疗组1治疗前后比较,差异有统计学意义(P<0.05);(4)HR-HPV16/18型的清除率:4组比较差异无统计学意义(P>0.05)。结论宫颈上药锡类散治疗HR-HPV疗效更显著,安全性高;宫颈细胞学转阴较高危型HPV转阴可能延迟;针对16/18型HPV治疗效果欠佳。
Objective To explore the clinical effect of different vaginal drugs for treating cervical high-risk (HR) human papillomavirus (HR-HPV) infection. Methods Two hundreds and forty patients meeting the inclusion criteria were randomly divided into the four groups.The treatment group 1 adopted Xilei Powder,the treatment group 2 adopted recombinant human interferon alpha-2b suppository,the treatment group 3 adopted Ruibeisheng Female Kangdu Jieyin compound,and the control group adopted normal saline to rub the cervix.The four groups withal adopted vaginal cervical medication,starting on 3 d after menstrual cleanliness,once every other day for 6 weeks,and stopped medication during menstruation.The therapeutic effects were observed and conducted the comparative analysis. Results (1) The HR-HPV negative conversion rate:the treatment groups had significant increase,moreover the treatment group 1 was better than other treatment groups ( P <0.05);(2) the HR-HPV DNA quantitation:the treatment groups had significant decrease,and the treatment group 1 was superior to other groups( P <0.05);(3) the negative conversion rate of cervical cytology:the intra-group comparison of treatment groups had no statistical difference( P >0.05),there was statistically significant difference between before and after treatment in the treatment group 1( P <0.05);(4) the HR-HPV type 16/18 clearance rate:there was no statistically significant difference among the four groups ( P > 0.05). Conclusion The vaginal medication of Xilei Powder is more effective with high safety in the treatment of HR-HPV infection;the negative conversion of cervical cytology may be delayed compared with HR-HPV;the treatment effect aiming at HPV type 16/18 is poor.
作者
杨敬红
谢秀超
张潇月
何丝思
陈艾
YANG Jinghong;XIE Xiuchao;ZHANG Xiaoyue;HE Sisi;CHEN Ai(Department of Obstetrics and Gynecology,Mianyang Municipal Hospital of TraditionalChinese Medicine,Mianyang,Sichuan 621000,China)
出处
《重庆医学》
CAS
2019年第11期1878-1881,共4页
Chongqing medicine
